TNFRSF17 and neoplasm: They observed the downregulation of BCMA through non-truncating missense mutations or in-frame deletions in the extracellular domain of BCMA, in addition to tumor intrinsic resistance mechanisms that occurred at relapse after anti-BCMA CAR T therapy [73].